E2007

Phase 3Small molecule

Eisai

E2007 is one of 159 small molecule programs targeting Seizure. It is currently in Phase 3.

Indications

Total Trials

Active Trials

158

Competitors

Pipeline

Status by Indication[3][1]

Indication

SeizureActive, not recruiting

MigraineActive, not recruiting

EpilepsyActive, not recruiting

NeuralgiaActive, not recruiting

Diabetic NeuropathyActive, not recruiting

SeizurePhase 3

Active, not recruiting

MigrainePhase 2

Active, not recruiting

EpilepsyPhase 2

Active, not recruiting

NeuralgiaPhase 2

Active, not recruiting

Diabetic NeuropathyPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

357 competitors in Migraine

#DrugCompanyPhaseTrials

E2007

Eisai

Phase 3

1 2

Aimovig

Amgen

Preclinical

33 3

Emgality

Eli Lilly

Preclinical

19 4

Vyepti

Lundbeck

Preclinical

12 5

Bayer Aspirin

Bayer

Preclinical

2 6

Savella

AbbVie

Preclinical

2 7

Cymbalta

Alnylam Pharmaceuticals

Preclinical

1 8

Pristiq

PPrism Pharmaceuticals

Preclinical

1 9

Lidocain

Bayer

Preclinical

1 10

Bupivacaine Only

Pacira Pharmaceuticals, Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Parkinson's Disease7 trials

A Study of E2007 In Patients With Parkinson's Disease

Terminated· Eisai logo

Eisai·Phase 2·NCT00427011·25 enrolled

The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Completed· Eisai logo

Eisai·Phase 3·NCT00286897·702 enrolled

A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

Completed· Eisai logo

Eisai·Phase 2·NCT00165789·75 enrolled

Show 4 more trials

Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Terminated· Eisai logo

Eisai·Phase 3·NCT00360308·723 enrolled

The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations

Withdrawn· Eisai logo

Eisai·Phase 2·NCT00451633

A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Terminated· Eisai logo

Eisai·Phase 3·NCT00360412·997 enrolled

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period Dyskinesias

Completed· Eisai logo

Eisai·Phase 2·NCT01172379·2 enrolled

Seizure6 trials

Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)

Completed· Eisai logo

Eisai·Phase 3·NCT03201900·91 enrolled

An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)

Completed· Eisai logo

Eisai·Phase 2·NCT00849212·30 enrolled

Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures

Completed· Eisai logo

Eisai·Phase 2·NCT00416195·48 enrolled

Show 3 more trials

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Completed· Eisai logo

Eisai·Phase 3·NCT00699972·390 enrolled

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Completed· Eisai logo

Eisai·Phase 3·NCT00699582·389 enrolled

E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Completed· Eisai logo

Eisai·Phase 2·NCT00144690

Diabetic Neuropathy2 trials

An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

Completed· Eisai logo

Eisai·Phase 2/3·NCT00505284·352 enrolled

Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)

Completed· Eisai logo

Eisai·Phase 2/3·NCT00592904·262 enrolled

Epilepsy1 trial

Safety and Pharmacokinetics Study of E2007 to Treat Partial and Generalised Seizures in People With Epilepsy

Completed· Eisai logo

Eisai·Phase 2·NCT03780907·18 enrolled

Metabolism1 trial

An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of 14C-Perampanel in Healthy Male Subjects

Completed· Eisai logo

Eisai·Phase 1·NCT02116907·7 enrolled

2 more indications

Migraine1 trial

Efficacy and Safety Study of E2007 in Migraine Prophylaxis

Completed· Eisai logo

Eisai·Phase 2·NCT00154063·206 enrolled

Neuralgia1 trial

Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)

Completed· Eisai logo

Eisai·Phase 2·NCT00592774·146 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for E2007. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — E2007 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for E2007. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Eisai

E2007

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Parkinson's Disease7 trials

Seizure6 trials

Diabetic Neuropathy2 trials

Epilepsy1 trial

Metabolism1 trial

Migraine1 trial

Neuralgia1 trial

References

Drug Info

Quick Facts

Related News